Stock Watch: When Governments Step In
The Record Of State Intervention In Life Sciences Has Been Patchy
Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.
You may also be interested in...
Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align
Proposed decision withholds Medicare coverage from current and future amyloid-directed monoclonal antibody drugs for Alzheimer’s disease unless patients are enrolled in a randomized clinical trial.
The €70 million first close of Germany's Wellington Partners fourth fund on 19 September was widely lauded as a sign of recovery of the European venture capital market (scripintelligence.com, 19 September 2012). But a more tangible indication of value was the clinical progress announced in the same week by publicly-quoted German biotech Morphosys.
Updated results from a US government-funded study showed that long-term treatment with either Genentech's Lucentis (ranibizumab) or the much cheaper Avastin (bevacizumab) resulted in similar levels of visual improvement in patients with advanced age-related macular degeneration (AMD) – with clarity of vision with monthly treatments only slightly better than the as-needed (PRN) treatment group.